UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+9.04%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$5.59B
AUM Growth
+$865M
(+18%)
Cap. Flow
+$450M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
66.42%
Holding
655
New
83
Increased
132
Reduced
97
Closed
122
Top Buys
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$800M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$386M |
| 3 |
NEWR
New Relic, Inc.
NEWR
|
+$274M |
| 4 |
DEN
Denbury Inc.
DEN
|
+$189M |
| 5 |
VMW
VMware, Inc
VMW
|
+$172M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$230M |
| 2 |
PDCE
PDC Energy, Inc.
PDCE
|
+$221M |
| 3 |
UNVR
Univar Solutions Inc.
UNVR
|
+$219M |
| 4 |
FOCS
Focus Financial Partners Inc. Class A
FOCS
|
+$146M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$141M |
Sector Composition
| 1 | Technology | 34.96% |
| 2 | Healthcare | 28.93% |
| 3 | Real Estate | 5.18% |
| 4 | Financials | 4.45% |
| 5 | Consumer Discretionary | 4.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Disc Medicine
IRON
$2.1B
| $1.09M | 0.02% |
23,121
+6,000
| +35% | +$282K |
|
302
Marvell Technology
MRVL
$57.6B
| $1.08M | 0.02% |
20,000
+5,000
| +33% | +$271K |
|
303
Ocular Therapeutix
OCUL
$2.22B
| $1.07M | 0.02% |
342,111
+40,000
| +13% | +$126K |
|
|
RVNC
304
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.02M | 0.02% |
+88,800
| New | +$1.02M |
|
305
Schrodinger
SDGR
$1.43B
| $1.01M | 0.02% |
35,700
+21,500
| +151% | +$608K |
|
306
Acrivon Therapeutics
ACRV
$51.9M
| $1M | 0.02% |
105,000
+5,000
| +5% | +$47.8K |
|
307
Praxis Precision Medicines
PRAX
$843M
| $998K | 0.02% |
38,903
| – | – |
|
308
Dyne Therapeutics
DYN
$1.88B
| $992K | 0.02% |
110,752
-65,000
| -37% | -$582K |
|
309
Tarsus Pharmaceuticals
TARS
$2.38B
| $982K | 0.02% |
55,262
-48,000
| -46% | -$853K |
|
|
SLN
310
Silence Therapeutics
SLN
$246M
| $967K | 0.02% |
98,326
| – | – |
|
|
ACAH
311
DELISTED
Atlantic Coastal Acquisition Corp. Class A Common Stock
ACAH
| $965K | 0.02% |
90,632
| – | – |
|
312
Four Corners Property Trust
FCPT
$2.72B
| $960K | 0.02% |
+43,260
| New | +$960K |
|
313
PTC Therapeutics
PTCT
$4.64B
| $955K | 0.02% |
42,601
-2,500
| -6% | -$56K |
|
314
Cullinan Oncology
CGEM
$403M
| $950K | 0.02% |
105,000
+20,000
| +24% | +$181K |
|
315
California Resources
CRC
$4.27B
| $932K | 0.02% |
16,648
-356
| -2% | -$19.9K |
|
316
Astria Therapeutics
ATXS
$425M
| $925K | 0.02% |
124,000
+10,000
| +9% | +$74.6K |
|
317
AMC Entertainment Holdings
AMC
$1.44B
| $914K | 0.02% |
+114,421
| New | +$914K |
|
318
IQVIA
IQV
$32.2B
| $912K | 0.02% |
4,635
-11,000
| -70% | -$2.16M |
|
319
Jazz Pharmaceuticals
JAZZ
$7.8B
| $908K | 0.02% |
7,014
-7,200
| -51% | -$932K |
|
320
Ardelyx
ARDX
$1.58B
| $898K | 0.02% |
+220,000
| New | +$898K |
|
321
Wayfair
W
$11.2B
| $848K | 0.02% |
14,000
+4,000
| +40% | +$242K |
|
322
Informatica
INFA
$7.55B
| $843K | 0.02% |
40,000
-85,000
| -68% | -$1.79M |
|
323
SCYNEXIS
SCYX
$40.2M
| $835K | 0.01% |
366,019
-20,000
| -5% | -$45.6K |
|
|
OSI
324
DELISTED
Osiris Acquisition Corp.
OSI
| $832K | 0.01% |
80,570
| – | – |
|
|
BHAC
325
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
| $829K | 0.01% |
78,575
| – | – |
|